Wepox Injection contains Recombinant Human Erythropoietin Alfa (30000 IU), a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis, as well as anemia due to chemotherapy in cancer patients. Wepox Injection is also utilized in reducing the need for allogeneic blood transfusions in patients undergoing elective, non-cardiac, non-vascular surgery. The administration of Wepox should be individualized based on the patient’s hemoglobin levels, with careful monitoring to avoid excessive erythropoiesis, which may increase the risk of thromboembolic events. It is contraindicated in patients with uncontrolled hypertension and known hypersensitivity to erythropoietin or any component of the formulation. Adverse effects may include hypertension, headache, arthralgia, and injection site reactions. Dosage and frequency should be determined by a healthcare professional according to the severity of anemia and patient response. Wepox Injection should be used under strict medical supervision with regular monitoring of hemoglobin levels, blood pressure, and iron status to ensure optimal therapeutic outcomes and minimize potential risks.